1. Introduction
===============

The bacterial inhabitants of the human gastrointestinal tract constitute an enormously complex ecosystem that includes both aerobic and anaerobic microorganisms.^\[[@R1]\]^ The relevance and effect of resident bacteria on a host\'s physiology and pathology has been well documented.^\[[@R2]\]^ Major functions of the gut microflora include metabolic activities that result in salvage of energy and absorbable nutrients, trophic effects on intestinal epithelia and immune structure and function, and protection of the colonized host against invasion by alien microbes.^\[[@R3]\]^ Gut flora may play an essential role in certain pathological disorders, including multisystem organ failure, colon cancer, and even cardiovascular disease.^\[[@R4]\]^ Studies have shown therapeutic manipulation of the enteric microflora would benefit patients with irritable bowel syndrome, inflammatory bowel disease, and *Clostridium difficile* infection.^\[[@R5]--[@R7]\]^

Several attempts have been made to target the gut microbiota. Studies have shown that traditional Chinese herb could induce structural changes in gut microbiota, enrich the amounts of beneficial bacteria and benefit treatment of diabetes and prostate cancer.^\[[@R8],[@R9]\]^ A standardized Chinese herbal formula containing rhubarb and moutan bark, Dahuang Danpi Decoction (DDD), has been used in traditional Chinese medicine for gastrointestinal disease for nearly 2000 years. WF Li et al revealed that DDD could help to lower the level of CRP and the Randson scores in acute severe pancreatitis,^\[[@R10],[@R11]\]^ and also help to prevent and treat multiple organ dysfunction.^\[[@R12]\]^ However, the mechanism underlying DDD\'s impact on these status has barely been elucidated. A recent study revealed that rhubarb extract changed the microbial ecosystem, downregulated key markers of both inflammatory and oxidative stresses in acute-alcohol challenged mice.^\[[@R13]\]^ This study suggests that the gut microbiota might have a pivotal role in the effect of DDD on gastrointestinal disease.

*Lactobacillus bulgaricus* is one of the dominant probiotic strains in the gastrointestinal tract, which binds closely to the intestinal mucosa to form the biological barrier of the intestine and helps to maintain the gut microflora balance.^\[[@R14]\]^ In this study, we aim to evaluate the effect of DDD on *L bulgaricus* growth and lactic acid metabolite levels, to check DDD\'s impact on the gut microflora, which could be one mechanism for the effect of DDD on gastrointestinal disease.

2. Material and method
======================

2.1. Materials
--------------

MRS medium: 63 g of solid MRS (Thermo Fisher Scientific, Cambridge, MA) was dissolved in 1000 ml of distilled water, and sterilized. *L bulgaricus* lyophilized powder was purchased from Shandong Branch Ke Yi Biological Engineering Co., Ltd (Qingzhou, Shandong, China), and the total number of viable bacteria is about 1.28 × 10^10^ cfu/g.

2.2. Drugs
----------

DDD preparation: According to Zhang Zhongjing \"Golden Chamber", the formula in our study was composed of five herbs, namely: rhubarb 18 g, moutan bark 9 g, peach seed 12 g, waxgourd seeds 30 g, and Glauber\'s salt 9 g. Herbs were all provided and quality controlled by Guangzhou Xingyuanchun pharmacy (Guangzhou, Guangdong, China). Each unit of DDD formula yielded 1000 ml of decoction. The decoction was freeze-dried. Lyophilized samples were stored at −20 °C. Ceftriaxone sodium was purchased from Wuhan Berkha Bio-medical Co., Ltd (Wuhan, Hubei, China).

2.3. Culture of *L bulgaricus* and drug administration
------------------------------------------------------

We allocate MRS medium into 7 conical flasks. Each conical flask contained 100 ml MRS medium and 1 g *L bulgaricus* freeze-dried powder (about 1.28 × 10^10^ cfu/g). The powder was then mixed to make a suspension of bacteria with concentration of about 10^8^ cfu/ml. The 7 bottles were labeled and treated with the following drugs: 1 with blank; 2 to 4 with high, medium and low doses of DDD respectively; 5 to 7 with high, medium and low doses ceftriaxone sodium respectively. The concentration for high, medium and low dose were 40, 10, and 2.5 mg/ml. The fermentation was carried out for 24 hours at 37 °C with 5% CO~2~.

2.4. Strain growth stage determination and lactate metabolites measurement
--------------------------------------------------------------------------

Aliquots (100 μL) were taken every 2 hours for optical density (OD) measurement. Growth curve of *L bulgaricus* was determined measuring the increase of OD at 600 nm with a UV-1202 UV--VIS spectrophotometer (Thermo Fisher Scientific, Cambridge, MA). The culture medium supernatant was collected at 0, 2, 6, 10, 14, 18, and 22 hours. L and D lactic acid levels were measured by ELISA commercial kit from BIOVISON (E4356, Milpitas, CA). Each measurement was repeated three times and the average was used for later analyses.

2.5. Analysis
-------------

Data were analyzed by SPSS 13.0 software (SPSS v13.0) (ISPP Inc., Chicago, IL). Continuous data were presented as mean ± standard deviation. Shapiro--Wilk test was applied to test the normality of data. Repeated measures ANOVA test was used to analyze the levels of OD, L-lactic acid and D-lactic acid levels at different time points in different groups. Mauchly test was used to test the sphericity, and correction of the degree of freedom was applied if necessary. Multiple comparison between the groups was performed using S-L-D method. All tests were two-tailed, and statistical significance was considered to be *P \< *.05.

3. Results
==========

3.1. Effects of Dahuang Danpi Decoction and ceftriaxone on *L bulgaricus* in vitro growth
-----------------------------------------------------------------------------------------

The OD values of the *L bulgaricus* in each MRS medium are shown in Table [1](#T1){ref-type="table"}. As presented, the concentration of *Lactobacillus* at different time points and in different groups were significantly different (*P \< *.001). No significant difference in the concentrations of *Lactobacillus* was observed in the low DDD group and the control group. The *Lactobacillus* concentration in the high DDD group and the medium DDD group was significantly higher than those in the control group and those in the three ceftriaxone groups (*P \< *.001 for all). The concentration in the high DDD group was significantly higher than that in the medium DDD group (*P \< *.001). DDD shortened the lag phase of *L bulgaricus* (within 2 hours), prolonged the logarithmic phase (2--14 hours) and kept the stable period of high level reproduction (14--22 hours), especially in the 40 mg/ml DDD group. The *Lactobacillus* concentration in the ceftriaxone groups was significantly lower than that in the control group (*P \< *.001 for all). In the 3 ceftriaxone groups, no significant difference in *Lactobacillus* concentration was detected (*P = *.84).

###### 

Growth curve of Lactobacillus in different DDD and Ceftriaxone groups (λ = 600 nm).
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3.2. Effects of Dahuang Danpi Decoction and ceftriaxone on L-lactic acid levels
-------------------------------------------------------------------------------

The L-lactic acid concentrations in different groups are shown in Table [2](#T2){ref-type="table"}. As shown, the concentrations of L-lactic acid varied significantly at different time points and in different groups (*P \< *.001). We noted no significant changes in the L-lactic concentrations in the three ceftriaxone groups over time, and no significant difference was detected in the high and the medium ceftriaxone group (*P* = .15). Compared to the control group, the concentrations of L-lactic acid were significantly higher in the three DDD groups, while significantly lower in the three ceftriaxone groups (*P \< *.001 for all). The concentrations of L-lactic acid were highest in the high DDD group, followed by the medium DDD group and the low DDD group (*P \< *.001 for all).

###### 

Concentration of L-lactic acid in different concentrations of DDD and Ceftriaxone.
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3.3. Effects of Dahuang Danpi Decoction and ceftriaxone on D-lactic acid levels
-------------------------------------------------------------------------------

The D-lactic acid concentrations in different group are shown in Table [3](#T3){ref-type="table"}.

###### 

Concentration of D-lactic acid in different concentrations of DDD and Ceftriaxone.

![](medi-98-e13941-g003)

The concentrations of D-lactic acid at different time points and in different groups were significantly different (*P \< *.001). There was no significant difference of D-lactic acid levels between the control group and the medium DDD group (*P = *.214) and between the control group and the low DDD group (*P = *.13). The D-lactic acid levels in the high DDD group were significantly higher than those in the control group, the low and medium DDD group, respectively (*P \< *.001 for all). In the three ceftriaxone groups, the levels of D-lactic acid were significantly lower than those in the control group and all three DDD groups (*P \< *.001 for all). Compared to the low ceftriaxone group, the D-lactic acid levels in the medium and the high ceftriaxone group were significantly lower (*P \< *.001 for both), while no significant differences were detected between the medium and the high ceftriaxone group (*P = *.14).

4. Discussion
=============

In this pilot study, we found that Dahuang Danpi Decoction could dose-dependently promote the growth of *L bulgaricus* and enhance the secretion of L-lactic acid and D-lactic acid, which are the metabolites of *L bulgaricus.* Ceftriaxone could inhibit the growth and the metabolite secretion of *L bulgaricus*.

The human gut is a natural reservoir for numerous species of microorganisms. A mutualistic relationship between beneficial symbionts and commensals is important for the maintenance of health and wellbeing. Alterations in this balance can lead to dysbiosis and ultimately may result in clinical disease expression.^\[[@R15]\]^ Various disease states and treatments, especially antibiotics have profound influences on the presence and levels of various bacteria normally present in the human microbiome.^\[[@R16]--[@R19]\]^ In coeliac disease patients, level of IgA-coated bacteria is reduced and is associated with intestinal dysbiosis.^\[[@R16]\]^ The proportions of phylum Firmicutes and Clostridia were significantly reduced in the diabetic patients.^\[[@R17]\]^ Probiotics have been increasingly used in both prevention and treatment of a variety of diseases, including but not limited to inflammatory bowel disease, *C difficile* infection, and antibiotic-associated diarrhea.^\[[@R20]\]^*L bulgaricus* and other lactic-acid-producing lactobacilli are the main microorganisms classified as probiotic agents,^\[[@R20]\]^ and lactic acid is one of the underlying mechanism.^\[[@R21]\]^ By producing a high amount of lactic acid, lactic-acid-producing lactobacilli are able to inhibit the growth of other pathogenic microorganisms.^\[[@R21]\]^ In our work, DDD dose-dependently promoted the growth of *L bulgaricus* in different periods and significantly enhanced the secretion of both L-lactic acid and D-lactic acid, which suggests DDD could exert a dose-dependent modulation on the gut microbiota. The effect of modulation of gut microbiota can be one of the mechanisms of DDD treatment effect of gastrointestinal disease.

Our findings, as well as prior findings, all suggest a modulation effect of rhubarb on gut microbiota.^\[[@R13],[@R22]\]^ AM Neyrinck et al revealed that rhubarb extract could change the microbial ecosystem, and downregulated key markers of both inflammatory and oxidative stresses in rats.^\[[@R13]\]^ Peng Ying et al^\[[@R22]\]^ found that in the ileum of rhubarb-exposed rats, more bacterial diversity was observed. DDD formula, a form of polypharmacy, has been used in the treatment of gastrointestinal disease for over 2000 years in China. However, the underlying mechanism has barely been elucidated. Together with previous studies, our work suggested that gut microbiota might be involved. Moreover, we revealed that lactic-acid-producing lactobacilli in particular might be involved.

Our study has several limitations. One important limitation is that our study represents an in vitro study, and our results cannot be directly applied to humans. However, our study could be a useful preliminary study to investigate the effect of DDD on gut microbiota. Second, we only checked the effect of DDD on *L bulgaricus,* while the effect of DDD on other microorganism remained unclear and the effect of DDD may be affected by other microorganisms. Third, our work is not able to further identify the possible effective ingredients of DDD, which could lead to a more specific treatment plan. Forth, only 1 culture was done in each group. However, the *L bulgaricus* culture and measurement in our laboratory were quality controlled. Further studies involving other main microorganisms, in vivo studies and exploration of possible effective gradient such as paeonol are required.

Although generally considered safe, some studies have highlighted that probiotics may be ill advised in specific patient populations. Bacteremia,^\[[@R23]\]^ sepsis^\[[@R24]\]^ and meningitis^\[[@R25]\]^ have been described on rare occasions in children treated with probiotics. Our preliminary work suggested DDD could be a new way for prevention and treatment of dysbiosis, and may be able to further regulate the immune and inflammatory response and other disease which are associated with gut microbiota.^\[[@R26]\]^

In conclusion, our study suggests that Dahuang Danpi Decoction, the Chinese herbal formula could promote the growth of *L bulgaricus* and enhance metabolite secretion. This treatment revealed a beneficial effect on the import group of probiotics in the gut, which could be 1 mechanism of DDD treatment effect of gastrointestinal disease. Although further studies are in need to determine the in vivo effect, our work provides preliminary evidence that DDD might be able to interact with probiotics, and improve the gut microbiota, and DDD could be a new therapy for prevention and treatment of dysbiosis.
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